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We used pulsed-field gel electrophoresis analysis and
genotyping to compare clinical isolates of Bordetella per-
tussis  recovered since the early 1990s in Finland and
France, 2 countries with similar histories of long-term mass
vaccination with whole-cell pertussis vaccines. Isolates
from both countries were similar genetically but varied
temporally. 
T
he introduction of whole-cell pertussis vaccines (wP)
from the 1940s to the 1960s in many countries result-
ed in a dramatic decrease in illness and death from pertus-
sis. However, pertussis remains a considerable public
health problem worldwide. Indeed, the disease continues
to be endemic in vaccinated populations in Europe,
Australia, Canada, and the United States, with cyclic
increases at 3- to 5-year intervals, despite high vaccination
coverage (1,2). One of the major causes is waning of vac-
cine-induced immunity with time (1,3), but increased dis-
ease surveillance and use of biologic diagnosis are also
implicated. However, changes in the agent of the disease,
Bordetella pertussis, are of some concern. This bacterium
expresses adhesins such as filamentous hemagglutinin,
pertactin, fimbriae (FIM), and toxins such as pertussis
toxin, and adenylate cyclase-hemolysin (4). Recently, cir-
culating isolates were found to differ from the strains used
for the wP vaccines in the world (5–13). These observed
changes might modify the properties of the isolates and
affect the efficacy of pertussis vaccines.
In Europe, heterogeneity is high in epidemic situations
with respect to wP vaccines used and vaccination history
and strategy. However, Finland and France have imple-
mented similar mass wP vaccination programs with high
coverage for several decades. Since 1952, children in
Finland have been vaccinated with combined diphtheria-
tetanus wPvaccine (DTwP) at 3, 4, and 5 months and from
20 to 24 months of age. The wP vaccine contains 2 strains
and has remained unchanged since 1976. Since 1959, chil-
dren in France have been vaccinated with DTwP-inactivat-
ed polio vaccine at 3, 4, and 5 months and from 16 to 18
months of age. The vaccine calendar for primary vaccina-
tion was changed to 2, 3, and 4 months of age in 1995. The
same wPvaccine, composed of 2 strains, has been used for
>40 years. In both Finland and France, incidence of pertus-
sis has increased and the disease has shifted to older age
groups, especially adolescents and adults. The cycles of
pertussis disease are observed every 3–5 years (5,13). The
aim of this study was to analyze and compare the isolates
circulating in the 2 European countries with long-term and
intensive vaccination.
B. pertussis isolates were selected from collections of
the Finnish Pertussis Reference Laboratory of the National
Public Health Institute (Turku, Finland) and the French
Pertussis National Center of Reference (Paris, France). Of
the 503 Finnish isolates recovered from 1991 to 2004, 64
were selected either because they represent all available
isolates from 1 community (Paimio) or they were recov-
ered from a geographic area as wide as possible. In addi-
tion, 6 isolates from a school outbreak that occurred in
Heinavesi (Finland) in 1982 were included to study the
changes over time. Of the 1,049 French isolates recovered
from 1991 to 2004, we selected 61 because they are repre-
sentative of the French collection from a temporal and geo-
graphic viewpoint and they correlate with the different
cycles of pertussis observed in France and Finland.
All Finnish and French isolates showed a high similar-
ity with a minimum of 80.3% overall relatedness by using
pulsed-field gel electrophoresis (PFGE) analysis after
digestion of B. pertussis genomic DNA with XbaI restric-
tion enzyme (14) (Appendix Figure, available online at
http://www.cdc.gov/ncidod/EID/vol12no06/05-
1283_app.htm). Most Finnish and French isolates fell into
PFGE groups III, IV, and V (Appendix Figure and Figure,
panel A) corresponding to the isolates circulating in
Europe from 1999 to 2001 (14). A new PFGE group (VII)
was identified among Finnish isolates recovered in 2004
(Appendix Figure and Figure, panel A). This new profile,
with 97.3% level of relatedness (Appendix Figure), might
represent an emerging group. The new profile was further
confirmed with PFGE by using the second restriction
endonuclease SpeI (data not shown), as previously recom-
mended (5,14). We cannot say whether PFGE VII isolates
are actually emerging or whether evidence for their emer-
gence is anecdotal, as is the case with French PFGE VI
isolates, which represent only 0.6% of French isolates
(data not shown).
We previously showed that the major PFGE group cir-
culating in Europe from 1999 to 2001 is group IV (14). In
France and in Finland, the PFGE group IV was overrepre-
sented from 1992 to 2004 with 85.3% level of relatedness,
confirming the limited polymorphism of B. pertussis.
PFGE group IV was subdivided into 3 subgroups, α, β,
and γ, whose frequencies varied between countries (14). In
our study, we show that, as in France (5) the PFGE groups
of the isolates circulating in Finland vary temporally with
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Panel A). However, the frequency of the isolate subgroups
circulating in Finland and France was different. In fact, the
major subgroup detected in Finland between 1992 and
1999 was IVγ; since 2000, subgroups IVα and IVβ have
been found (Figure, Panel A). This circumstance is well
illustrated among the isolates recovered in Paimio,
where 99% of isolates with IVγ were circulating in 1992
whereas, in 2004, 42% of subgroup IVβ, 33% of subgroup
IVα, 25% of the new group VII, and none of IVγ were
circulating in Paimio. Subgroups IVα and β, absent from
1992 to 1994, are now circulating. However, subgroup
IVα is not a new subgroup in Finland since the 6 isolates
collected in Heinavesi in 1982 exhibit this profile
(Appendix Figure).
The analysis also included genotyping of the genes
encoding pertussis toxin S1 subunit (ptxA) and pertactin
(prn) and serotyping of FIM, performed as described pre-
viously (5,13). The sequence of ptxA is the same (ptxA
allele type 1) for all Finnish and French isolates. The same
types of prn alleles are also harbored by Finnish and
French isolates (Appendix Figure). The emergence of iso-
lates harboring ptxA1 and  prn2 or  prn3  alleles in both
countries might be explained by the fact that the wP vac-
cine strains used in both countries harbor ptxA2 or A4 and
prn1 alleles (13,15). A similar hypothesis might be pro-
posed for the expression of FIM. In fact, most of the
Finnish isolates collected from 1991 to 2004 express
FIM2, whereas in France most of the isolates express
FIM3 (Figure, Panel B). The differences in the expression
of FIM between Finnish and French isolates might reflect
the difference in strains used for Finnish and French wP
vaccines. The Finnish wP vaccine contains 2 strains
expressing FIM2,3 and FIM3, whereas the French wP vac-
cine includes 2 strains expressing FIM2,3 and FIM2
(13,15). A marked shift of predominant serotype from
FIM2 to FIM3 has been observed in Finland since 1999,
although the wP vaccine remained the same. The emer-
gence of isolates with FIM3 and PFGE subgroup IVβ, a
new subgroup found in Finland, might be due to the
increase in the frequency of this subgroup in the neighbor-
ing countries and the increased mobility of people within
the European Union in the last decades.
We show that the B. pertussis isolates circulating in 2
countries with a long history of wP vaccination are genet-
ically close. In the 2 countries, similar PFGE groups and
subgroups are present, but their frequencies were different
in the 1990s. Further, the subgroup emerging according to
the cycles of pertussis in each country varies. The differ-
ence observed in frequency of subgroups could be due to
herd immunity or human density of the populations con-
cerned. Does this herd immunity vary depending on the
human genetic population concerned or are the vaccine
strains used expressing similar factors but not at the same
level (e.g., FIM2 vs. FIM3)? This question needs further
investigation.
These 2 countries have started using acellular pertussis
vaccines, France since 2002 and Finland since 2005.
Continued monitoring of the circulating isolates will be
important.
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Figure. A) Pulsed-field gel electrophoresis profile repartition of
Bordetella pertussis isolates by year and by country. B) Fimbriae
expression of B. pertussis isolates by year and by country. FIN,
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